苏马特里普坦-纳普罗用于急性偏头痛治疗:一项随机试验
Jan Lewis Brandes1, David Kudrow, Stuart R Stark
1Nashville Neuroscience Group, Nashville, Tenn 37203, USA. jbrandes@nashvilleneuroscience.com
JAMA
|April 5, 2007
概括
一个固定剂量药片,结合了sumatriptan和naproxen,有效地治疗了急性偏头痛,比单独的药物提供了更好的好处. 这种组合疗法在缓解偏头痛方面表现出良好的安全性.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 偏头痛的发病过程涉及多种机制,这表明组合疗法可能比单一疗法更有效.
- 评估用于治疗急性偏头痛的sumatriptan和naproxen的固定剂量组合.
研究的目的:
- 评估苏马特里普坦-纳普罗森片对急性偏头痛单疗法和安慰剂的疗效和安全性.
- 为了比较头痛缓解,光恐惧症,语音恐惧症,恶心和持续无痛反应.
主要方法:
- 两项随机双盲研究包括1461名和1495名中度至重度偏头痛患者.
- 患者接受固定剂量药片 (苏玛85毫克/纳普罗森500毫克),单疗法 (苏玛85毫克或纳普罗森500毫克) 或安慰剂.
- 主要结局:头痛缓解2小时,没有光恐惧症/音恐惧症/恶心,持续2-24小时无疼痛反应.
主要成果:
- 与安慰剂相比,苏马特里普坦-纳普罗森显著改善了头痛缓解,光恐惧症和语音恐惧症.
- 持续无疼痛反应 (2-24小时) 在组合治疗与单一治疗和安慰剂相比更优越.
- 组合治疗和苏马特里普坦单独治疗之间的不良事件发生率相似.
结论:
- 固剂量苏马特里普坦-纳普罗森片在治疗急性偏头痛方面提供了优越的临床益处,与单一治疗相比.
- 这种组合疗法耐受性良好,并呈现出可接受的不良反应特征.
更多相关视频
08:33A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
Published on: January 5, 2024
05:49An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies
Published on: November 1, 2024
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...